6:29 PM
 | 
Oct 08, 2008
 |  BC Extra  |  Clinical News

Novartis reports PAH data for imatinib

Novartis (NYSE:NVS; SWX:NOVN) said top-line data from a Phase II trial in 59 patients with pulmonary arterial hypertension (PAH) refractory to standard therapy showed that 400 mg oral imatinib...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >